Patent controversy embroils South Korean biotech claiming key CRISPR IP
Questions emerge about whether ToolGen properly acquired foundational gene editing patents, and how much government support founder Kim Jin-soo received for his breakthrough invention.
To read more
Register for limited access
Register to receive our weekly newsletter and access two of our subscriber-only articles per month.
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10